Biotech Beach
Filter News
Found 75,697 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2023
12/2/2023
Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 90,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 106,500 shares of Arcutis’ common stock to 7 newly hired employees.
-
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
12/1/2023
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 27,000 restricted stock units of Atara’s common stock to three newly hired employees.
-
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
12/1/2023
Zentalis® Pharmaceuticals, Inc. announced that on December 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 42,000 shares of the Company’s common stock and 28,000 restricted stock units to one newly hired employee.
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - December 01, 2023
12/1/2023
ORIC Pharmaceuticals, Inc. announced that on December 1, 2023, ORIC granted a total of 23,080 non-qualified stock options and 3,840 restricted stock units to three new non-executive employees who began their employment with ORIC in November 2023.
-
NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
12/1/2023
Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023.
-
Neurocrine Biosciences to Host Analyst Day on December 5, 2023
12/1/2023
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, will hold its Analyst Day focused on its R&D portfolio and strategy on Tuesday, December 5, 2023 in New York.
-
Mammogen to Showcase New Data at SABCS 2023 Demonstrating Clinical Efficacy of Its genTRU-breast™ qPCR Blood Test in Early-Stage Breast Cancer
12/1/2023
Mammogen, a pioneering leader in women's health and a subsidiary of early detection parent company, IVBH, is set to present groundbreaking clinical data at the 2023 San Antonio Breast Cancer Symposium (SABCS).
-
Despite recent layoffs and closures in the state, there are still many companies actively recruiting for roles in California.
-
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
11/30/2023
Aptose Biosciences Inc. announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer.
-
Bright Uro Announces $23M Series A Funding Round Led by Laborie – Expands Senior Leadership Team to Accelerate Next Phase of Commercialization
11/30/2023
Bright Uro announced the initial closing of its $23M Series A financing round led by Laborie Medical Technologies, a leading global provider of urology diagnostic and therapeutic solutions.
-
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
11/30/2023
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis.
-
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
11/30/2023
CG Oncology, Inc. today announced that Phase 3 monotherapy data from the BOND-003 clinical trial evaluating the efficacy and safety of cretostimogene grenadenorepvec in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG), showed that 75.7% of evaluable patients achieved a complete response (CR) at any time, as of the cutoff date of October 5, 2023.
-
Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study
11/30/2023
Polaris Group, announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis.
-
Bayer and CrossBay Medical to develop novel Intrauterine System Inserter
11/30/2023
Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.
-
Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13
11/30/2023
Inipharm today announced that it has begun dosing in a Phase 1 study of INI-822, its orally-delivered small molecule inhibitor of HSD17B13.
-
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome
11/30/2023
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS).
-
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®
11/30/2023
ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson’s disease (PD).
-
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
11/30/2023
Immix Biopharma, Inc. today announced that it will present and host institutional investor meetings at the 2023 JMP Securities Hematology and Oncology Summit.
-
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
11/30/2023
Cidara Therapeutics, Inc. today announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress.